z-logo
open-access-imgOpen Access
Should we spare neoadjuvant chemotherapy in low-risk muscle-invasive bladder cancer patients scheduled for radical cystectomy?
Author(s) -
Günter Niegisch
Publication year - 2019
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2019.04.04
Subject(s) - cystectomy , bladder cancer , medicine , cisplatin , chemotherapy , oncology , neoadjuvant therapy , urology , cancer , breast cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here